- Home
- GNTA
as 10-17-2025 3:46pm EST
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
| Founded: | 2014 | Country: | Italy |
| Employees: | N/A | City: | N/A |
| Market Cap: | 59.7M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 8.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.56 - $6.20 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Genenta Science S.p.A. News
GNTA Breaking Stock News: Dive into GNTA Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Genenta Science And 2 Other Penny Stocks To Consider
Newsfile
5 months ago
Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference
GlobeNewswire
5 months ago
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
GlobeNewswire
6 months ago
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
MT Newswires
7 months ago
Genenta Science Obtains $21.9 Million Financing to Expand Pipeline
GlobeNewswire
7 months ago
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
Simply Wall St.
8 months ago
February 2025 US Penny Stocks With Promising Prospects
Insider Monkey
8 months ago
Is Genenta Science S.p.A. (GNTA) the Best Italian Stock to Buy in 2025?
Compare GNTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GNTA Genenta Science S.p.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.